Page 19 - IMR Annual Report 2022: Institute for Medical Research

Annual
IMR
Report2022 3
INSTITUTE FOR MEDICAL RESEARCH

AIRC Research Highlights

Principal
investigator/
No. Research Title NMRR Co-principal
Number
investigator
(Co-PI)

1 Characterising COVID-19 vaccine responses using host NMRR ID- Norfarhana
genomics & transcriptomics analyses: A pilot study 22-00733- Khairul Fahmy
SD7
2 Study on the immune response after first dose of Pfizer- NMRR-21- Dr. Shuwahida
BioNTech and Sinovac vaccines among recovered 290-58771 Shuib
COVID-19 patients and non-infected COVID-19 subjects

3 Evaluation of serum neurofilament light chain as a NMRR-21- Dr. Shuwahida
biomarker for disease activity in multiple sclerosis 411-58817 Shuib
patients

4 Post-vaccination COVID-19 immunity and disease NMRR-21- Co-PI:
surveillance in Malaysia (IMSURE) 411-58817 Dr. Masita Arip

5 Characterization of clinical grade CD19 chimeric NMRR- Dr. Adiratna
antigen receptor T (CAR-T) cells for potential adoptive 21-1106- Mat Ripen
immunotherapy treatment in acute lymphoblastic 60217
leukemia using automated CliniMACS Prodigy system

6 Identification of drug-specific genetic basis and NMRR-21- Dr. Too Chun
evaluation of clinical effectiveness in biologic DMARDs 73-58111 Lai
and targeted synthetic DMARDs for treatment
stratification of rheumatoid arthritis
7 A pilot study of genetic and immunological profiling of NMRR- Dr. Siti
type 1 diabetes mellitus of Malaysian children 20-2847- Fatimah
57019 Abdullah

8 Association of HLA-Related pharmacogenomics NMRR- Dr. Nurul Aain
markers and dapsone-induced severe cutaneous 20-2593- Ahmad Fauzi
adverse reactions (SCARs)/ liver injury (DILI) in a multi- 57036
ethnic Malaysian population

9 Exploration of single cell transcriptomics in regulatory T NMRR- Jamiila Ismail
cells among renal transplant recipients 20-2407-
56371

10 Identification of genetic landscape of primary NMRR- Dr. Adiratna Research Centre (AIRC) Allergy & Immunology
immunodeficiency (PID) in Malaysia 20-2387- Mat Ripen
56356
11 Longitudinal study of neutralizing antibody response NMRR- Co-PI:
among COVID-19 patients in Malaysia 20-1676- Dr. Masita Arip
55108

12 Generation of an RNA-based vaccine for COVID-19 NMRR-20- Dr. Masita
764-54569 Arip/ Ching
Yee Ming

13 MRGPRX2 variation and expression of neuromuscular NMRR- Dr.
blocking agents (NMBA)-induced perioperative 20-2490- Mohammed
pseudo-allergic anaphylaxis for risk profiling: a pilot 57178 Faizal Bakhtiar
study